Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$127.3 million.

  • Myriad Genetics' Consolidated Net Income fell 23.98% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of -$127.3 million for FY2024, which is 51.65% up from last year.
  • Latest data reveals that Myriad Genetics reported Consolidated Net Income of -$127.3 million as of FY2024, which was up 51.65% from -$263.3 million recorded in FY2023.
  • In the past 5 years, Myriad Genetics' Consolidated Net Income ranged from a high of -$27.2 million in FY2021 and a low of -$263.3 million during FY2023.
  • Moreover, its 3-year median value for Consolidated Net Income was -$127.3 million (2024), whereas its average is -$167.5 million.
  • As far as peak fluctuations go, Myriad Genetics' Consolidated Net Income plummeted by 6,337.50% in 2020, and later soared by 87.84% in 2021.
  • Myriad Genetics' Consolidated Net Income (Yearly) stood at -$199.6 million in 2020, then reached -$223.7 million in 2020, then skyrocketed by 87.84% to -$27.2 million in 2021, then crashed by 311.76% to -$112.0 million in 2022, then slumped by 135.09% to -$263.3 million in 2023, then spiked by 51.65% to -$127.3 million in 2024.